Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Rama Research LLC

Neither a doctor nor a teaching hospital

Research payments

$912,096

307 payments

Through program year 2025, Rama Research LLC is reported as receiving $912,096 in research payments, across 307 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $123,105 9
2024 Research $139,117 30
2023 Research $102,819 101
2022 Research $221,530 125
2021 Research $39,426 25
2020 Research $143,794 8
2019 Research $142,306 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $313,031 12 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $154,642 57 payments
  3. Amgen Inc. $144,920 15 payments
  4. AstraZeneca Pharmaceuticals LP $122,485 4 payments
  5. Eli Lilly and Company $75,643 7 payments
  6. AstraZeneca UK Limited $47,372 2 payments
  7. Genentech, Inc. $45,444 10 payments
  8. Alnylam Pharmaceuticals Inc. $8,559 200 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $224,620 4 payments
  2. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $169,857 6 payments
  3. BAY94-8862 LCM HFmr/pEF (EF 40%) $83,589 29 payments
  4. Galactic-Hf $73,801 4 payments
  5. A Randomized Double-Blind Placebo-Controlled Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $52,933 2 payments
  6. Phase 1c Selnoflast Proof of Concept $45,444 10 payments
  7. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $42,364 4 payments
  8. A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $37,947 11 payments
  9. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $35,547 3 payments
  10. BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti $33,106 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record